Epigenetic Biomarker Discovery in HPV related HNSCC

HPV 相关 HNSCC 中表观遗传生物标志物的发现

基本信息

批准号：
8837907
负责人：
Joseph A Califano
金额：
$ 16.36万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-04-01 至 2015-09-18
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8837907
关键词：
Affect Age Area Biological Assay Biological Markers Blood Body Fluids Cancer Control Cervix carcinoma Characteristics Clinical DNA DNA Methylation Data Detection Development Diagnostic Diagnostic Neoplasm Staging Disease Epidemiology Epigenetic Process Gender Genetic Genome Genomic Segment Genomics HPV-High Risk Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Health Human Papillomavirus Incidence Malignant Neoplasms Measurement Methods Methylation Microscopic Modality Pap smear Pathologic Patients Performance Plasma Population Premalignant Recurrence Resolution Risk Saliva Salivary Sampling Secondary Prevention Smoking Staging Techniques Testing United States Validation alcohol exposure base bisulfite sequencing case control cost effective design epigenetic marker malignant mouth neoplasm malignant oropharynx neoplasm multiplex detection novel novel strategies oral premalignancy performance tests population based pre-clinical prognostic response screening tobacco exposure treatment response viral DNA

项目摘要

DESCRIPTION (provided by applicant): High risk human papilloma virus related head and neck squamous cell carcinoma (HPVHNSCC) incidence is rapidly increasing, and will soon surpass the incidence of cervical carcinoma in the US. There are no effective ways to detect preclinical or early HPVHNSCC, screen populations at increased risk for HPVHNSCC development, or even assay for microscopic persistence of HPVHNSCC after therapy. However, epigenetic alterations have been detected in body fluids from premalignant and early stage cancers and multiplex tests have shown promise for identification of patients with oral premalignancy. Our primary hypothesis is that multiplex testing of plasma and salivary rinses based on HPVHNSCC specific epigenetic alterations combined with high risk HPV DNA presence has potential as useful test for presence of HPVHNSCC. This project will serve as a discovery and diagnostic validation biomarker development trial for HPVHNSCC detection with potential application for assessment of disease response and development of a population based screening test.

描述（申请人提供）：在美国，高危人乳头瘤病毒相关头颈鳞状细胞癌（HPVHNSCC）发病率正在迅速增加，很快将超过宫颈癌的发病率。没有有效的方法来检测临床前或早期 HPVHNSCC、筛查 HPVHNSCC 发生风险增加的人群，甚至检测治疗后 HPVHNSCC 的微观持续性。然而，在癌前和早期癌症的体液中检测到表观遗传改变，并且多重测试已显示出识别口腔癌前患者的希望。我们的主要假设是，基于 HPVHNSCC 特异性表观遗传改变与高危 HPV DNA 的存在相结合，对血浆和唾液冲洗液进行多重检测，有可能成为检测 HPVHNSCC 是否存在的有用方法。该项目将作为 HPVHNSCC 检测的发现和诊断验证生物标志物开发试验，具有评估疾病反应和开发基于人群的筛查测试的潜在应用。